A review of the literature concerning the use of oral and depot antipsychotic medication has highlighted some important considerations in the treatment of chronic schizophrenic patients. All patients not treated with any form of antipsychotic drug will relapse within 3 years. These relapses will be more clinically significant and will occur at greater frequency than in patients who receive medication on a regular basis. Careful consideration should be given to each patient when choosing between oral or depot medication and inpatient or outpatient therapy. In addition, the clinician should consider the dosage schedule of each medication and balance this against the probability of extrapyramidal side effects and noncompliance. One option for the prevention of relapse without an increase in adverse side effects is the administration of depot haloperidol. For all therapeutic options, medication should be given on a regular basis, since intermittent dosing strategies do not work, and psychosocial rehabilitation should be initiated.
|Original language||English (US)|
|Number of pages||7|
|Journal||Journal of Clinical Psychiatry|
|Issue number||3 SUPPL.|
|State||Published - 1993|
ASJC Scopus subject areas
- Psychiatry and Mental health